StockMarketWire.com - Benchmark, the aquaculture biotechnology and food chain sustainability business, expects revenues to be in line with market forecasts, and adjusted EBITDA to be in the range £8.7m to £9.3m, for the full year.

It said that overall performance across the group had been good, with strong growth in sales in the breeding and genetics division, and improved market conditions for the advanced animal nutrition division in the second half.

A trading update said: "The animal health division continues to manage a valuable portfolio of products in development, and the board remains confident of delivering the company's medium and long term strategy of an increasingly diversified portfolio of both products and services.

"The group is approaching the launch of commercial field trials of its innovative new sea lice treatment, and is closely engaged with major salmon producers, with the bulk of the equipment and licences for the trials now in place.

"Management are confident that commercial field trials will start before the end of December 2017, although the exact timing of these trials remains unclear and they are unlikely to commence before the end of September.

"Consequently, contributions attributable to this new product are unlikely to be recognised in FY17."




Story provided by StockMarketWire.com